Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00255099
Status:
COMPLETED
Last Update Posted:
2011-06-15
First Post:
2005-11-15
Brief Title:
TMC125-C216 A Phase III Study to Investigate the Efficacy Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen Including TMC114Ritonavir and an Investigator-selected Optimized Background in HIV-1 Infected Patients With Limited to no Treatment Options
Sponsor:
Tibotec Pharmaceuticals Ireland
Organization:
Tibotec Pharmaceuticals Ireland
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-12
Start Date Type:
None
Primary Completion Date:
2007-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-07
Completion Date Type:
ACTUAL
First Submit Date:
2005-11-15
First Submit QC Date:
November 15 2005
Study First Post Date:
2005-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2011-06-02
Disp First Submit QC Date:
June 2 2011
Disp First Post Date:
2011-06-15
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2011-06-02
Last Update Post Date:
2011-06-15
Last Update Post Date Type:
ESTIMATED